Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF

OBJECTIVE: The use of alemtuzumab, a humanized monoclonal anti-CD52 antibody has changed the therapy of highly active relapsing-remitting MS (RRMS). Alemtuzumab infusion depletes most lymphocytes in peripheral blood, whereas differential recovery of immune cells, probably those with a less CNS-autor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurol Neuroimmunol Neuroinflamm
Autors principals: Möhn, Nora, Pfeuffer, Steffen, Ruck, Tobias, Gross, Catharina C., Skripuletz, Thomas, Klotz, Luisa, Wiendl, Heinz, Stangel, Martin, Meuth, Sven G.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7007635/
https://ncbi.nlm.nih.gov/pubmed/31826986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000654
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars